Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

Shinobi Security | 688 followers on LinkedIn. Built for builders. Trusted by breakers. | We build skilled and reliable AIs for ethical hacking. https://shinobi.security

Shinobi provides specialized consulting services on Chinese negotiating tactics and insider threats to help you safely conduct business with or even in China.

Nov 13, 2023 · It is almost impossible to say exactly when the first ninja, or more correctly “shinobi”, arose, since the functions of spies and assassins are frequent throughout history …

Chief Scientific Officer at Shinobi Therapeutics · Experience: Shinobi Therapeutics · Education: University of Washington School of Medicine · Location: Houston · 500+ connections on …

Introducing Shinobi Therapeutics! Today we announced a $51M Series A to fuel our work creating hypoimmune CD8ɑβ iPS-T cell therapies for cancer and beyond.

Shinobi would be the first Japanese biotech startup to receive lead investments from the world's top investors in the US in recent years.

Exclusive: Cell therapy startup Shinobi adds Borges as science chief, Katz as top medical officer endpts.com 4

We are incredibly excited to announce the launch of Shinobi Therapeutics with $51M in Series A funding!

🎉 SHINOBI Launch Party Recap! 🎮 A few weeks ago, we celebrated the release of our newest title from the Legend Collection—SHINOBI: Art of Vengeance—with an epic launch party! From ...